Skip to main content

Animations

MJFF Publications

2731 - 2740 of 6570 Results
Title
Year
  • Year
  • 2021
  • 2021
  • 2021
  • 2021
  • 2023
  • 2021
  • 2021
  • 2021
  • 2021
  • 2023
  • Summary Details
    OPEN
    Title: Mitochondrial Defects in Fibroblasts of Pathogenic MAPT Patients
    Journal Name: Frontiers in Cell and Developmental Biology
    Publisher: Frontiers Media SA
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.3389/fcell.2021.765408
    Citation Count: 10
  • Summary Details
    OPEN
    Title: Structural basis of polyamine transport by human ATP13A2 (PARK9)
    Journal Name: Molecular Cell
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1016/j.molcel.2021.08.017
    Citation Count: 49
  • Summary Details
    OPEN
    Title: The Added Benefit of Opicapone When Used Early in Parkinson's Disease Patients With Levodopa-Induced Motor Fluctuations: A Post-hoc Analysis of BIPARK-I and -II
    Journal Name: Frontiers in Neurology
    Publisher: Frontiers Media SA
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.3389/fneur.2021.754016
    Citation Count: 18
  • Summary Details
    OPEN
    Title: Glucosylceramide in cerebrospinal fluid of patients with GBA-associated and idiopathic Parkinson’s disease enrolled in PPMI
    Journal Name: npj Parkinson's Disease
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1038/s41531-021-00241-3
    Citation Count: 55
  • Summary Details
    OPEN
    Title: Blood transcriptomic signatures associated with molecular changes in the brain and clinical outcomes in Parkinson’s disease
    Journal Name: Nature Communications
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1038/s41467-023-39652-6
    Citation Count: 56
  • Summary Details
    OPEN
    Title: Decrease in Skin Prion-Seeding Activity of Prion-Infected Mice Treated with a Compound Against Human and Animal Prions: a First Possible Biomarker for Prion Therapeutics
    Journal Name: Molecular Neurobiology
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1007/s12035-021-02418-6
    Citation Count: 21
  • Summary Details
    OPEN
    Title: Contribution of rare variant associations to neurodegenerative disease presentation
    Journal Name: npj Genomic Medicine
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1038/s41525-021-00243-3
    Citation Count: 22
  • Summary Details
    OPEN
    Title: Carlos II of Spain, ‘The Bewitched’: cursed by aspartylglucosaminuria?
    Journal Name: BMJ Neurology Open
    Publisher: BMJ
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc
    DOI - Digital Object Identifier: 10.1136/bmjno-2020-000072
    Citation Count: 1
  • Summary Details
    OPEN
    Title: The AKT modulator A-443654 reduces α-synuclein expression and normalizes ER stress and autophagy
    Journal Name: Journal of Biological Chemistry
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1016/j.jbc.2021.101191
    Citation Count: 40
  • Summary Details
    OPEN
    Title: Application of Aligned-UMAP to longitudinal biomedical studies
    Journal Name: Patterns
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1016/j.patter.2023.100741
    Citation Count: 53
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.